



Antibiotics and Infectious Respiratory Diseases, 2nd Edition

Guest Editors:

Dr. Francesco Di Gennaro

Clinic of Infectious Diseases,
University of Bari, 70121 Bari,
Italy

Dr. Fabrizio Palmieri

Director of Respiratory Infectious
Diseases Unit, National Institute
for Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Dr. Gina Gualano

Respiratory Infectious Diseases
Unit, National Institute for
Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Deadline for manuscript
submissions:

closed (1 July 2024)



Message from the Guest Editors

Dear Colleagues.

Infectious respiratory diseases (IRD) continue to be among the leading causes of morbidity and mortality globally, and in the age of the COVID-19 pandemic. They can be caused by viruses, bacteria, parasites, or opportunistic infections; nevertheless, indiscriminate antibiotic usage in their treatment has resulted in the development of antimicrobial resistance. The effective management of respiratory infectious illnesses in order to lessen their burden and avoid antibiotic misuse has become a major therapeutic and public health concern. Manuscripts addressing the following topics are also welcome:

1. Antimicrobial resistance and bacterial host resistance;
2. New antibiotics for MDR infection;
3. HAP (hospital-acquired pneumonia), VAP (ventilator-associated pneumonia), and CAP (community-acquired pneumonia) are the three types of pneumonia;
4. Nontuberculous mycobacteria (NTM) and tuberculosis;
5. SARS CoV2 interstitial pneumonia and viral pneumonia;
6. Antimicrobial resistance and antimicrobial prescription education;
7. Infection with pneumonia in immunocompetent and immunocompromised people.



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi